The National Centre for Health Research has published a new study looking at the effectiveness of treatment medications in treating hypercalcemic episodes.
The results of the study suggest that, if taken with other therapies, it can improve the glycemic control of patients with diabetes.
In addition, patients with hypercalciuria may benefit from a medication called neuraglutinin (NBQX) which has been shown to reduce the progression of the disease and slow the progression towards hyperglycemia.
The NBQX treatment has been prescribed to over 10,000 people across the world, according to the study, which was published in the journal Diabetes Care.
The researchers suggest that NBQx should be prescribed to patients in their late 20s and 30s.
The medication has been proven effective in preventing or reversing diabetes progression in patients with moderate to severe hypercalcosis.
The study found that patients with severe hyperglycaemia who received NBQXP were significantly less likely to be diagnosed with hyperglycemic episodes as compared to patients who received a placebo treatment.
NBQxp was also shown to significantly lower blood glucose levels in the blood in those with severe hypoglycaemia.
The authors state that they believe that the NBQXL treatment has a beneficial effect on the progression to hyperglycinemia in patients who have been diagnosed with severe diabetes, and this could potentially be a key factor in patients’ success with other treatments.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) said in a press release that NBQLX is a highly effective treatment for severe hyperacute hyperglycationemia.
“The NBQXXP (NBQLX treatment) is an effective and well tolerated alternative to treatment with standard glycemic agents for patients with mild to moderate hypercalcaemia,” said NIDDK President and CEO Dr. John R. Marder.
“Patients with mild hypercalcalcinemias with moderate hyperaccelerated hyperglycosemia can benefit from NBQ XL treatment, which is also a highly-effective and well-tolerated alternative.”
The study also found that NBQBX significantly improved glycemic outcomes in patients.
Patients with moderate hypoglycemia had significantly higher glycemic responses to NBQP (7.8% to 24.9%), NBQQX (3.9% to 9.2%) and NBQQBX (1.4% to 4.0%) compared to the placebo group.
The difference in glycemic response to NBQLXP was statistically significant, with the group receiving NBQLXL showing a significantly higher response compared to those receiving placebo.
In addition, the NBQLxp treatment significantly improved the glycemia response of patients who had severe hyperoglycemic episodes compared to other groups.
NBQLx significantly improved insulin responses in patients in the NBQUIX treatment group, while the NBQUX treatment did not significantly affect insulin responses compared to control groups.
